Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment ...

LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) Phase 2 study in patients with decompensated cirrhosis. Treatment with LPCN 1148 in the ...

Lipocine (LPCN) announced that the U.S. FDA has granted Fast Track Designation to LPCN 1148 as a treatment for sarcopenia in patients with ...

Lipocine Inc. (LPCN), a biopharmaceutical company, Tuesday said that the U.S. Food and Drug Administration or FDA has granted Fast ...

Lipocine (LPCN) announced that the U.S. FDA has granted Fast Track Designation to LPCN 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis. LPCN 1148, an oral prodrug of ...

(RTTNews) - Lipocine Inc. (LPCN), a biopharmaceutical company, Tuesday said that the U.S. Food and Drug Administration or FDA has granted Fast Track Designation to LPCN 1148, the company's drug ...

US FDA grants fast track designation to Lipocine’s LPCN 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis: Salt Lake City Thursday, December 19, 2024, ...

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Lipocine Inc.’s LPCN 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis. LPCN 1148, an oral ...